JPS6191135A - γ−インタフエロン（γ−ＩＦＮ）を含有するリユ−マチ症治療剤 - Google Patents

γ−インタフエロン（γ−ＩＦＮ）を含有するリユ−マチ症治療剤

Info

Publication number
JPS6191135A
JPS6191135A JP60188689A JP18868985A JPS6191135A JP S6191135 A JPS6191135 A JP S6191135A JP 60188689 A JP60188689 A JP 60188689A JP 18868985 A JP18868985 A JP 18868985A JP S6191135 A JPS6191135 A JP S6191135A
Authority
JP
Japan
Prior art keywords
therapeutic agent
agent according
interferon
treats
rheumatism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP60188689A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0544930B2 (enExample
Inventor
ヨハン　フリードリツヒ　フオン　アイヒボルン
フランツ　リンク
ハンス　ヨアヒム　オベルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioferon Biochemische Substanzen GmbH and Co
Original Assignee
Bioferon Biochemische Substanzen GmbH and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6247225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS6191135(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioferon Biochemische Substanzen GmbH and Co filed Critical Bioferon Biochemische Substanzen GmbH and Co
Publication of JPS6191135A publication Critical patent/JPS6191135A/ja
Publication of JPH0544930B2 publication Critical patent/JPH0544930B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP60188689A 1984-10-05 1985-08-29 γ−インタフエロン（γ−ＩＦＮ）を含有するリユ−マチ症治療剤 Granted JPS6191135A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE3436638A DE3436638C2 (de) 1984-10-05 1984-10-05 Verwendung von Interferon-gamma (IFN-gamma) enthaltenden Präparationen zur Behandlung rheumatischer Erkrankungen
DE3436638.5 1984-10-05
EP85107490.6 1985-06-18

Publications (2)

Publication Number Publication Date
JPS6191135A true JPS6191135A (ja) 1986-05-09
JPH0544930B2 JPH0544930B2 (enExample) 1993-07-07

Family

ID=6247225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60188689A Granted JPS6191135A (ja) 1984-10-05 1985-08-29 γ−インタフエロン（γ−ＩＦＮ）を含有するリユ−マチ症治療剤

Country Status (5)

Country Link
EP (1) EP0180737B1 (enExample)
JP (1) JPS6191135A (enExample)
AT (1) ATE45675T1 (enExample)
DE (2) DE3436638C2 (enExample)
ZA (1) ZA857721B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6212724A (ja) * 1985-05-30 1987-01-21 ベ−リンガ−　インゲルハイム　インタ−ナシヨナルゲゼルシヤフト　ミツト　ベシユレンクテルハフツンク ＩＦＮ−ｒ含有医薬組成物
JPH09208489A (ja) * 1996-10-25 1997-08-12 Hayashibara Biochem Lab Inc γ−インターフェロン感受性疾患剤

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) * 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
EP0311616B1 (en) * 1986-06-17 1991-09-25 Biogen, Inc. Combinations of gamma interferons and anti-inflammatory or anti-pyretic agents for treating diseases
CA1320905C (en) * 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
DE4238159A1 (en) * 1992-11-12 1993-04-29 Josef Dr Med Mueller Treatment of prim. chronic polyarthritis and diabetes mellitus - comprises administration of gamma-interferon
US6299871B1 (en) * 1998-07-24 2001-10-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Orally-administrable therapeutic and/or prophylactic agent for HTLV-1-related diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5527168A (en) * 1978-04-11 1980-02-27 Verronmay Ltd Drug composition
JPS5877824A (ja) * 1981-10-13 1983-05-11 エクソバ−，インコ−ポレイテイド インターフェロンを含む組成物
JPS59134735A (ja) * 1982-09-16 1984-08-02 ウイリアム・アルビン・カ−タ− 抗腫瘍組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5598118A (en) * 1979-01-18 1980-07-25 Hayashibara Takeshi Preparation of type-2 interferon and drug containing the same
EP0305551A3 (en) * 1981-10-13 1990-01-10 Exovir, Inc. Pharmaceutical compositions for topical application
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
DE3381553D1 (de) * 1982-10-25 1990-06-21 Genentech Inc Synergistische humaninterferonaktivitaet.
US4483849A (en) * 1983-01-07 1984-11-20 Carter William A Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
JP3108538B2 (ja) * 1992-08-13 2000-11-13 松下電工株式会社 平面トランス

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5527168A (en) * 1978-04-11 1980-02-27 Verronmay Ltd Drug composition
JPS5877824A (ja) * 1981-10-13 1983-05-11 エクソバ−，インコ−ポレイテイド インターフェロンを含む組成物
JPS59134735A (ja) * 1982-09-16 1984-08-02 ウイリアム・アルビン・カ−タ− 抗腫瘍組成物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6212724A (ja) * 1985-05-30 1987-01-21 ベ−リンガ−　インゲルハイム　インタ−ナシヨナルゲゼルシヤフト　ミツト　ベシユレンクテルハフツンク ＩＦＮ−ｒ含有医薬組成物
JPH09208489A (ja) * 1996-10-25 1997-08-12 Hayashibara Biochem Lab Inc γ−インターフェロン感受性疾患剤

Also Published As

Publication number Publication date
ATE45675T1 (de) 1989-09-15
EP0180737A2 (de) 1986-05-14
EP0180737A3 (en) 1986-05-28
DE3436638C2 (de) 1992-10-08
DE3436638A1 (de) 1986-04-17
EP0180737B1 (de) 1989-08-23
ZA857721B (en) 1986-09-24
JPH0544930B2 (enExample) 1993-07-07
DE3572441D1 (en) 1989-09-28

Similar Documents

Publication Publication Date Title
ES2310931T3 (es) Analogos de interferon alfa humano de baja toxicidad.
Kobayashi et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.
Bhardwaj et al. IL-6/IFN-beta 2 in synovial effusions of patients with rheumatoid arthritis and other arthritides. Identification of several isoforms and studies of cellular sources.
Brodie et al. Functional IL-4 receptors on mouse astrocytes: IL-4 inhibits astrocyte activation and induces NGF secretion
DK174585B1 (da) Anvendelse af gamma-inteferon til fremstilling af farmaceutiske præparater til systemisk behandling af forskellige sygdomme hos mennesker i lave doser
Cunningham et al. gamma Interferon production appears to predict time of recurrence of herpes labialis.
DK171647B1 (da) Polypeptid, der er et interleukin-1 alfa-derivat, gen, der koder for polypeptidet, vektor indeholde nde genet, mikroorganisme indeholdende vektoren, og lægemiddel indeholdende polypeptidet
AU599031B2 (en) Regulation of degradation processes in bone
Chong et al. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
JPH07503851A (ja) 改良インターフェロン及びヒトの末梢血液白血球からのその製造方法
US4946674A (en) Process for treatment of rheumatic diseases
ES2243942T3 (es) Isoforma intracelular del antagonista del receptor de la interleuquina.
Chen et al. Production of osteoclast‐activating factor by normal human peripheral blood rosetting and nonrosetting lymphocytes
EP0098862A1 (en) Interferon-alpha 76
JPS6191135A (ja) γ−インタフエロン（γ−ＩＦＮ）を含有するリユ−マチ症治療剤
JPS6154040B2 (enExample)
EP0311616B1 (en) Combinations of gamma interferons and anti-inflammatory or anti-pyretic agents for treating diseases
EP0087686A2 (en) Homogeneous human immune interferon and process therefor
CA1282354C (en) INTERFERON .alpha. 54
RU2105566C1 (ru) Способ интерферонотерапии ю.а.севрука
US7012062B2 (en) Use of modified lysozyme C to prepare medicinal compositions for the treatment of some serious diseases
JP3048533B2 (ja) 低投与量にてアレルギー疾患を系統的に治療するための組換えヒトγ−インタフェロン含有組成物
CA2632024A1 (en) Treatment of multiple sclerosis using interferon-tau
Cachard et al. Enhancement of mouse interferon production by combined treatment of C-243 cells with butyric acid and theophylline
RU2237484C1 (ru) Способ лечения вич-инфицированных больных

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees